Etanercept is minimally effective in 2 children with atopic dermatitis.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of American Academy of Dermatology

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.JAAD.2005.03.013PMID 16021144
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Etanercept: An overview.

  2003cited by this paper
• The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis

  2001cited by this paper
• The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group.

  2001cited by this paper
• Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.

  2000cited by this paper
• A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis.

  1998cited by this paper

• Galectins in inflammatory skin diseases: current roles and future directions.

  2025cites this paper
• Targeting fibroblast TNF receptor 1 attenuates type 17 skin inflammation.

  2025cites this paper
• The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment

  2023cites this paper
• Advances in Current Drugs and Formulations for the Management of Atopic Dermatitis.

  2023cites this paper
• The Interactions Between Autoinflammation and Type 2 Immunity: From Mechanistic Studies to Epidemiologic Associations

  2022cites this paper
• An Insight on atopic dermatitis therapy: from conventional to Lipid based nanocarriers

  2020cites this paper
• Current and Future Monoclonal Antibodies in the Treatment of Atopic Dermatitis

  2020cites this paper
• The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders

  2020cites this paper
• New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines.

  2019cites this paper
• Comparative Safety of Systemic Immuno-modulatory Medications in Adults with Atopic Dermatitis.

  2019cites this paper
• Atopic dermatitis: a review of evolving targeted therapies

  2019cites this paper
• Management of Atopic Dermatitis

  2019cites this paper
• Biologics for the Treatment of Atopic Dermatitis

  2018cites this paper
• The Key Role of TNF-TNFR2 Interactions in the Modulation of Allergic Inflammation: A Review

  2018cites this paper
• Occupational and Environmental Skin Disorders

  2018cites this paper
• New and Future Therapies

  2018cites this paper
• Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment

  2018cites this paper
• Use of Systemic Immuno-Modulatory Medications in Children with Atopic Dermatitis

  2018cites this paper
• Toll‐like receptor 4 attenuates a murine model of atopic dermatitis through inhibition of langerin‐positive DCs migration

  2018cites this paper
• Alternative Nonsteroidal Therapies for Occupational and Environmental Allergic Skin Disorders

  2018cites this paper
• Monoclonal antibodies for the treatment of atopic dermatitis

  2018cites this paper
• Biological therapies for atopic dermatitis: An update.

  2018cites this paper
• Tumor Necrosis Factor Inhibition

  2018cites this paper
• Immunologic, microbial, and epithelial interactions in atopic dermatitis.

  2018cites this paper
• Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential

  2017cites this paper
• Role of Immunologists in the Development of Health Care System

  2017cites this paper
• Pathophysiologie der atopischen Blepharokeratokonjunktivitis

  2017cites this paper
• Biologics in patients with skin diseases

  2017cites this paper
• Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: a review

  2017cites this paper
• Off-Label uses of Biologic Agents Approved for Psoriasis and Psoriatic Arthritis for Dermatological Conditions: Part II

  2017cites this paper
• Future Trends on Treatment of Atopic Dermatitis

  2017cites this paper
• Systemic therapies in atopic dermatitis: The pipeline.

  2017cites this paper
• Biological Therapeutic Treatment of Atopic Dermatitis

  2017cites this paper
• Systemic therapy of atopic dermatitis

  2017cites this paper
• Novel Therapeutic Approaches to Atopic Dermatitis

  2017cites this paper
• Beyond Psoriasis: Novel Uses for Biologic Response Modifiers in Pediatric Dermatology

  2016cites this paper
• Novel Biologicals for the Treatment of Allergic Diseases and Asthma

  2016cites this paper
• Off-Label uses of Biologic Agents Approved for Psoriasis and Psoriatic Arthritis for Dermatological Conditions: Part I

  2016cites this paper
• ETFAD/EADV Eczema task force 2015 position paper on diagnosis and treatment of atopic dermatitis in adult and paediatric patients

  2016cites this paper
• Cellular and molecular immunologic mechanisms in patients with atopic dermatitis.

  2016cites this paper
• Biological Treatments in Atopic Dermatitis

  2015cites this paper
• Past, present, and future for biologic intervention in atopic dermatitis

  2015cites this paper
• The Multi-Modal Immune Pathogenesis of Atopic Eczema.

  2015cites this paper
• Systemic therapy of childhood atopic dermatitis.

  2015cites this paper
• EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

  2015cites this paper
• The translational revolution and use of biologics in patients with inflammatory skin diseases.

  2015cites this paper
• The Multi-Modal Immune Pathogenesis of Atopic

  2015cites this paper
• Applications des biomédicaments dans la dermatite atopique et l’urticaire chronique

  2014cites this paper
• Systemic therapy for atopic dermatitis

  2014cites this paper
• Systemic Treatment of Severe Atopic Dermatitis in Children and Adults

  2014cites this paper
• New era of biologic therapeutics in atopic dermatitis

  2013cites this paper
• Immunology of atopic eczema: overcoming the Th1/Th2 paradigm

  2013cites this paper
• Omalizumab for the treatment of atopic dermatitis.

  2012cites this paper
• Long Term Treatment Concepts and Proactive Therapy for Atopic Eczema

  2012cites this paper
• Safe and Effective Medicines for Children

  2012cites this paper
• Management of itch in atopic dermatitis.

  2011cites this paper
• Therapeutic Perspectives in Atopic Dermatitis

  2011cites this paper
• Nuevas perspectivas terapéuticas en dermatitis atópica Atopic dermatitis. New therapies for the future

  2011cites this paper
• Update on the management of chronic eczema: new approaches and emerging treatment options

  2010influential citation
• 24. Atopic Dermatitis

  2010cites this paper
• Effector pathways during eczematous dermatitis: where inflammation meets cell death

  2009cites this paper
• The antimicrobial protein psoriasin (S100A7) is upregulated in atopic dermatitis and after experimental skin barrier disruption.

  2009cites this paper
• Update on the Management of Atopic Dermatitis/Eczema

  2009cites this paper
• Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy.

  2009cites this paper
• Systemic therapeutic options for severe atopic dermatitis

  2009cites this paper
• Actualizacin en el tratamiento sistmico de la dermatitis atpica severa del adulto

  2009cites this paper
• Cellular and molecular mechanisms in atopic dermatitis.

  2009cites this paper
• Cutaneous adverse effects of biological therapies for psoriasis.

  2008cites this paper
• Topical tacrolimus in atopic dermatitis : Effects of long-term treatment on skin and respiratory symptoms

  2008cites this paper
• Alefacept for moderate to severe atopic dermatitis: a pilot study in adults.

  2008cites this paper
• Atopic dermatitis: therapeutic concepts evolving from new pathophysiologic insights.

  2008cites this paper
• Uso de fármacos biológicos en dermatosis fuera de la indicación aprobada. Segunda parte: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab y cetuximab

  2008cites this paper
• Atopic dermatitis: a review of recent advances in the field

  2008cites this paper
• Are Biologics Safe in the Treatment of Atopic Dermatitis? A Review with a Focus on Immediate Hypersensitivity Reactions

  2008cites this paper
• [Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab].

  2008cites this paper
• Immuntherapie der atopischen Dermatitis

  2007cites this paper
• Antipsoriatic biologic agents for the treatment of atopic dermatitis.

  2007cites this paper
• Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab.

  2007cites this paper
• 37 - Drugs that act on the immune system: Cytokines and monoclonal antibodies

  2007cites this paper
• Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report.

  2006cites this paper
• Steroids versus other immune modulators in the management of allergic dermatoses

  2006cites this paper
• The effect of etanercept on the human cutaneous allergic response.

  2006cites this paper
• Emerging therapeutic options for atopic dermatitis: Beyond TIMs

  2006cites this paper
• Off-label uses of biologic agents in dermatology: a 2006 update.

  2006cites this paper
• Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report

  2006cites this paper
• Clinical, Cosmetic and Investigational Dermatology Dovepress Update on the Management of Chronic Eczema: New Approaches and Emerging Treatment Options

  year unknowncites this paper
• Mechanisms of allergic diseases Cellular and molecular immunologic mechanisms in patients with atopic dermatitis

  year unknowncites this paper